Alterity Therapeutics Ltd (ATHE) Stock Analysis

Alterity Therapeutics Ltd (ATHE) is a publicly traded company in the HEALTHCARE sector. It trades at $4.07, carries a market capitalization of $75.94M. This page summarizes the public market data, fundamentals, and frequently asked questions for ATHE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Alterity Therapeutics Ltd currently has a Neutral sentiment score of 0.08.

About Alterity Therapeutics Ltd

Alterity Therapeutics Ltd is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of innovative therapies for Parkinson's disease and other neurodegenerative disorders. The company focuses on addressing significant unmet medical needs through its proprietary drug candidates and cutting-edge research programs. Committed to scientific excellence and collaborative approaches, Alterity strives to enhance patients' quality of life while advancing the field of ...

GNG Research Analysis

GNG Research scores Alterity Therapeutics Ltd (ATHE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ATHE.

Frequently Asked Questions

Does ATHE pay dividends?

Alterity Therapeutics Ltd (ATHE) does not currently pay a regular dividend.

What is ATHE's market cap?

Alterity Therapeutics Ltd (ATHE) has a market capitalization of $75.94M with a current stock price of $4.07.